Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
AssigneeSecarna Pharmaceuticals GmbH & Co. KG
InventorsFrank Jaschinski, Tamara Thelemann
Life of this patent
Estimating the term…
Abstract
The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
Claims8
An oligonucleotide capable of hybridizing with a nucleic acid sequence of the ectonucleotidase (NTPdase) CD39 of SEQ ID NO.1 (human) consisting of a sequence selected from the group consisting of SEQ ID NO. 89, SEQ ID NO.91, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.97, SEQ ID NO.93, SEQ ID NO.94, SEQ ID NO.23, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21, SEQ ID NO.22, SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26, SEQ ID NO.27, SEQ ID NO.28, SEQ ID NO.29, SEQ ID NO.30, SEQ ID NO.31, SEQ ID NO.32, SEQ ID NO.33, SEQ ID NO.34, SEQ ID NO.35, SEQ ID NO.36, SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40, SEQ ID NO.41, SEQ ID NO.42, SEQ ID NO.43, SEQ ID NO.44, SEQ ID NO.45, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.51, SEQ ID NO.52, SEQ ID NO.88, SEQ ID NO.90, SEQ ID NO.92, SEQ ID NO.95, SEQ ID NO.96 and combinations thereof, wherein at least one nucleotide of the oligonucleotide is LNA modified.
Dependencies are inferred from the claim text.